Koppe-Schmeißer Franziska, Fengler Karl, Kresoja Karl-Patrik, Lurz Philipp, Rommel Karl-Philipp
Department of Cardiology, University Medical Center of the Johannes Gutenberg University, Langenbeckstraße 1, 55131, Mainz, Germany.
Department of Cardiology, Heart Center at University of Leipzig and Leipzig Heart Institute, Leipzig, Germany.
Heart Fail Rev. 2025 Jan 29. doi: 10.1007/s10741-025-10489-z.
Renal Denervation (RDN) has emerged over the last decade as a third pillar in the treatment of arterial hypertension, alongside pharmacotherapy and lifestyle modifications. Mechanistically, it reduces central sympathetic overactivation, a process also relevant to heart failure. In this mini-review, we summarize the development of RDN for heart failure, discuss the current evidence supporting its effects, and provide an outlook on future developments.
在过去十年中，肾去神经支配术（RDN）已成为治疗动脉高血压的第三大支柱，与药物治疗和生活方式改变并驾齐驱。从机制上讲，它可减少中枢交感神经过度激活，这一过程也与心力衰竭相关。在这篇小型综述中，我们总结了RDN在心力衰竭治疗方面的发展，讨论了支持其疗效的现有证据，并对未来发展进行了展望。
